RR

Rick Ryan

Cultivation Capital Life Sciences; Apertus Pharmaceuticals

Ballwin, Missouri

Invests in

Sectors:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $3,500,000.00
  • Target Investment:

    $1,800,000.00

Work Experience

  • General Partner

    2013

    Cultivation Capital Life Sciences provides late seed/Series A venture funding to life science related companies. We are interested in opportunities in Healthcare IT and Services, Medical Devices, Pharmaceutical/Biotech, Biomedical Research Tools/reagents/Diagnostics, .

  • President

    2011

    Consulting Services: Strategy and Innovation for Life Science Companies Over 35 years experience in both early stage ventures and Fortune 500 multinational corporations, with expertise in technical development/commercialization, general management & P&L responsibilities, and international scope.

  • Exec Chairman

    2024

    API SERVICES Apertus is managed and staffed by highly experienced people with relevant backgrounds with fine chemicals, biotech and pharmaceutics. Let us help you with your API needs. FORMULATION DEVELOPMENT Our team has experience developing sterile injectables, potent fomulations, nasal sprays, DEA regulated products, topical creams, liquids, tablets capsules and suppositories. CONTRACT MANUFACTURING Apertus specializes in manufacturing suppositories, capsule, tablet and topical products. We manufacture small to medium sized batches of prescription drug products in our FDA-inspected Saint Louis facility. ANALYTICAL DEVELOPMENT Our team has experience developing and validating HPLC, GC, wet bench, and dissolution tests for API and drug product release testing. Nearly all of our own release testing is performed in-house.

2012 - 2024

  • Chief Executive Officer

    2012 - 2024

2006 - 2010

  • Vice President, Drug Discovery Business Unit

    2006 - 2010

    Drug Discovery and Development provides products and services to advance the discovery and development of NCE's and Biopharmaceuticals..

1999 - 2006

  • President

    1999 - 2006

    LINCO was a leader in the development and commercialization of research diagnostic kits (RIA, ELISA and Luminex xMAP platforms). It was acquired in May 2006 by Serologicals. Serologicals was acquired by Millipore in July 2006.

1996 - 1998

  • Vice President, Global Commercial Development

    1996 - 1998

    Responsible for global commercial development of novel vaccines and new products/services to support the Innovoject vaccination system..

1982 - 1996

  • Various Dir and Mgr level positions

    1982 - 1996

    Director International Marketing 1993-1996 Director Strategic Planning 1991-1993 Director Product/Commercial Development 1987-1991 Manager R&D 1982-86